These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 2026740

  • 1. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T, Nery L, Hales I.
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH, Chen JF, Yang BY, Liu RT, Tung SC, Chien WY, Lu YC, Kuo MC, Hsieh CJ, Wang PW.
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [Abstract] [Full Text] [Related]

  • 3. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B, Puavilai G, Rajatanavin R.
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [Abstract] [Full Text] [Related]

  • 4. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
    Sajjinanont T, Rajchadara S, Sriassawaamorn N, Panichkul S.
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
    [Abstract] [Full Text] [Related]

  • 5. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S, Karner I.
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [Abstract] [Full Text] [Related]

  • 6. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
    Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A.
    J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
    Franklyn JA, Betteridge J, Holder R, Sheppard MC.
    Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
    [Abstract] [Full Text] [Related]

  • 10. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C, Golia F, Vignali E, Pinchera A.
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [Abstract] [Full Text] [Related]

  • 11. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL, Holgado S, Alonso N, Salinas I, Granada ML, Sanmartí A.
    Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
    [Abstract] [Full Text] [Related]

  • 12. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
    Moon JH, Jung KY, Kim KM, Choi SH, Lim S, Park YJ, Park DJ, Jang HC.
    Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY, Weetman AP, Eastell R.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
    [Abstract] [Full Text] [Related]

  • 14. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G.
    Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
    [Abstract] [Full Text] [Related]

  • 15. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.
    Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M.
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):425-32. PubMed ID: 7955453
    [Abstract] [Full Text] [Related]

  • 16. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW, Yeung SS.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
    [Abstract] [Full Text] [Related]

  • 17. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
    López Alvarez MB, Hawkins F, Rigopoulou D, Martínez G, Jodar E, Estenoz J, Ortuño B, Arnaiz F.
    Med Clin (Barc); 1999 Jan 30; 112(3):85-9. PubMed ID: 10074614
    [Abstract] [Full Text] [Related]

  • 18. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment.
    Eftekhari M, Asadollahi A, Beiki D, Izadyar S, Gholamrezanezhad A, Assadi M, Fard-Esfahani A, Fallahi B, Takavar A, Saghari M.
    Hell J Nucl Med; 2008 Jan 30; 11(3):160-3. PubMed ID: 19081859
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
    Frusciante V, Carnevale V, Scillitani A, Zingrillo M, Dicembrino F, Giannatempo GM, Ghiggi MR, Minisola S.
    Eur J Nucl Med; 1998 Feb 30; 25(2):139-43. PubMed ID: 9473261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.